EuroPCR 2023 | More Evidence in Favor of Renal Denervation

This study included 219 patients with uncontrolled essential hypertension who had received at least two antihypertensive drugs. All of them underwent a renal angiography and were randomized to the renal denervation group or the control group.

EuroPCR 2023 | Stenting en chimenea vs BASILICA para la prevención de obstrucción coronaria durante el TAVI

Denervation was performed using the SyMapCath I catheter and the SYMPIONEER S1 generator/stimulator.

Mean patient age was 45 years old, and 87% of subjects were male.

The composite primary endpoint was a decrease in-office systolic blood pressure below 140 mmHg for noninferiority with the control group and changes in antihypertensive drugs in both number of drugs and doses at 6 months.

In-office systolic blood pressure was approximately 159 mmHg. After denervation, it decreased on average 25.2 mmHg in those who received denervation, and 27.3 mmHg in the control group. The difference was 2.69% (95% confidence interval: 4.11% to 9.83%), reaching noninferiority with a 10-% margin.

The drug index increased in both groups, indicating the need for more medication in higher doses to achieve blood pressure control, being lower in those who underwent denervation (4.37 vs. 7.61; p = 0.003).

Read also: EuroPCR 2023 | Events after Redo TAVR in Balloon-Expandable Valves.

Drug adherence—analyzed by urinalysis—was high and similar in both groups (around 90% at 6 months).

In terms of procedural safety, no patient died and there was no severe renal artery injury in those who underwent denervation. Major adverse events were reported in 10% of those who underwent denervation vs. 9.2% (p = 0.823).

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of

Reference: The SMART Study, presentado por el Dr. Jie Wang en el Congreso EuroPCR 2023, realizado en París, Francia.

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology